Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I F Tannock

Showing results (51-60 of 183) with videos related to

Pageof 19
Sort By:
Cancer Research|January 1, 1972
The proliferation of capillary endothelial cellsI F Tannock, S Hayashi
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Chemotherapy for patients with hormone-refractory prostate cancerF Joly, I F Tannock
British Journal of Cancer|June 1, 1986
Variation of pO2 in the growth medium of spheroids: interaction with glucose to influence spheroid growth and necrosisI F Tannock, I Kopelyan
British Journal of Cancer|January 1, 1997
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecanV Vukovic, I F Tannock
Cancer Research|August 15, 1989
Acid pH in tumors and its potential for therapeutic exploitationI F Tannock, D Rotin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1986
Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancerI F Tannock, G Browman
Seminars in Oncology|December 1, 1996
Overview of Canadian trials in hormonally resistant prostate cancerM J Moore, I F Tannock
Cancer|August 1, 1980
Chemotherapy for adenocystic carcinomaI F Tannock, D J Sutherland
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2014
Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancerI F Tannock, G R Pond
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapyK A Phillips, I F Tannock
Pageof 19

Showing results (51-60 of 183) with videos related to

Sort By:
Pageof 19
Cancer Research|January 1, 1972
The proliferation of capillary endothelial cellsI F Tannock, S Hayashi
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Chemotherapy for patients with hormone-refractory prostate cancerF Joly, I F Tannock
British Journal of Cancer|June 1, 1986
Variation of pO2 in the growth medium of spheroids: interaction with glucose to influence spheroid growth and necrosisI F Tannock, I Kopelyan
British Journal of Cancer|January 1, 1997
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecanV Vukovic, I F Tannock
Cancer Research|August 15, 1989
Acid pH in tumors and its potential for therapeutic exploitationI F Tannock, D Rotin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1986
Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancerI F Tannock, G Browman
Seminars in Oncology|December 1, 1996
Overview of Canadian trials in hormonally resistant prostate cancerM J Moore, I F Tannock
Cancer|August 1, 1980
Chemotherapy for adenocystic carcinomaI F Tannock, D J Sutherland
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2014
Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancerI F Tannock, G R Pond
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapyK A Phillips, I F Tannock
Pageof 19